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There are numerous pesticides and toxic chemicals in the environment that have yet to be
evaluated for potential to cause developmental neurotoxicity. Recent legislation and testing
initiatives provide an impetus to generating more information about potential hazards to children. In
the United States, the 1996 Food Quality Protection Act (FQPA) required the U.S. Environmental
Protection Agency (U.S. EPA) to make a finding that a pesticide food use is safe for children. In
addition, the law requires U.S. EPA to incorporate an additional 10-fold factor in risk assessments
for pesticide residue tolerances to take into account the special sensitivities of infants and children
as well as incomplete data with respect to toxicity and exposures. The potential of chemicals in
food and drinking water to cause endocrine disruption will also be examined via the Endocrine
Disruptor Screening and Testing Program required by the FQPA and the 1996 Safe Drinking Water
Act. In addition, a new voluntary chemical information program will provide screening-level
information for the some 2,800 high-volume chemicals in commerce in the United States. These
initiatives will need to be accompanied by research focused on developmental toxicity for children,
including developmental disabilities. Developmental disabilities exact a large toll on children's
health in the United States. Three major developmental disabilities-autism, cerebral palsy, and
severe mental retardation-each affect substantial numbers of children. We know very little about
the etiology of these conditions. A number of priority areas for research are suggested, including a
large environmental prospective study of developmental neurotoxicity. Key words: chemical
testing, child health, developmental disabilities, neurotoxicity, pesticides, risk assessment.
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Children are our most important national
resource. Children's brain, development, and
behavior are important to their health, to their
ability to contribute to society throughout life,
and to the well-being offuture generations.
Children cannot makechoices abouttheirenvi-
ronment; it is up to adults to make the right
decisions to ensure that they are protected.
Scientists haveasignificant role toplay in assur-
ing that these protections are provided to our
children by identifying preventable causes of
developmental disabilities and impairment.
Federally funded research has played a critical
role in identification oflong-term effects on the
developing brain ofexposures to lead, methyl
mercury, and polychlorinated biphenyls
(PCBs). It is critical that such research be
clearlytranslated into policy.
We know that infants and children may
be more susceptible than adults to some
chemicals (1), and their exposures to chemi-
cals in foods and in the environment are dif-
ferent, and often greater, than those for
adults. Proportionate to body weight, chil-
dren eat more ofcertain types offoods, drink
more fluids, and breathe more air than adults
(2). Toddlers crawl on the floor and grass
outside; the older children spend a lot oftime
outdoors. Thus, children are often more
exposed to potentially harmful pollutants.
A research agenda for public health is
driven by a number of factors that operate
simultaneously including scientific advances,
public policy concerns, and public health
value. As we come to the end ofthe National
Institutes ofHealth-declared "decade ofthe
brain," it is clear that the science of brain
development is developing rapidly. There is
good reason to expect that the research com-
munity is poised to make breakthroughs in
our understanding ofneurological develop-
ment and its disruption by exposures to envi-
ronmental agents. This article addresses some
ofthe policy and public health issues that are
relevant to an agenda for research in this area.
Specifically, it describes relevant develop-
ments in pesticide and chemical regulation
and assessment and the public health impact
ofdevelopmental disabilities in the United
States. This article does not attempt to delin-
eate all ofthe public policy controversies and
views ofall the players in this arena. Nor does





Pesticides constitute a variety ofchemical,
biologic, and other agents that are used to kill
or inhibit the growth ofpests of economic
importance. They include insecticides, fungi-
cides, herbicides, rodenticides, wood preserva-
tives, and disinfectants. In addition to these
toxic chemicals, many pesticides may have the
potential to cause developmental toxicity. In
the United States in 1995, there were 876 pes-
ticides on the market, ofwhich 489 were regis-
tered for use on food products. In 1997, there
were about 4 billion pounds used in the
United States. Of these, some 1.2 billion
pounds ofconventional pesticideswereapplied
in the United States, mostly for agricultural
purposes but also in the home and for other
uses (3). From the mid-1960s to 1980, pesti-
cide use sharply increased from 400 million
pounds to more than 800 million pounds per
year-an increase largely driven by the devel-
opment and use ofchemical herbicides in agri-
culture. In contrast, nonagricultural use
declined from 300 million to 200 million
pounds between 1970 and the 1990s (3). It is
not known to what extent use reflects risk,
since toxicityand exposure potential can differ,
poundfor pound, fordifferent pesticides.
The Food Quality Protection Act of
1996 (FQPA) is defined by its explicit pro-
tection of children; it was passed unani-
mously and signed into law in August 1996
(4). FQPA requires the U.S. Environmental
Protection Agency (U.S. EPA) to make more
realistic assessments of the risks posed by
exposures to pesticides by assessing aggregate
and cumulative risks, as described below.
Because ofthis law, over time some of the
current-and least safe-pesticide uses will
be replaced by safer ones or by nonchemical
alternatives, such as alternative agricultural
practices and biological pesticides.
The concepts for the children's health
components ofthe law came from the 1993
National Research Council (NRC) report,
Pesticides in the Diets ofInfants and Children
(2). The committeeconduded that thetoxicity
of, and exposures to, pesticides are frequently
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different for children and adults. Despite a
wealth ofscientific information to warrant
addressing risks to children, the U.S. EPA
did not adequately address those risks (2).
The committee advised the U.S. EPA to
incorporate information about dietary expo-
sures to children in risk assessments and aug-
ment pesticide testing with new or improved
guidelines for neurotoxicity, developmental
toxicity, endocrine effects, immunotoxicity,
and developmental neurotoxicity. It recom-
mended that the U.S. EPA include cumula-
tive risks from pesticides that act via a
common mechanism ofaction and aggregate
risks from nonfood exposures when develop-
ing a tolerance for a pesticide (2). The
Clinton Administration-the U.S. EPA, the
U.S. Department ofAgriculture, and the
Food and Drug Administration (FDA)
immediately announced an initiative to
address the NRC recommendations, includ-
ing asking Congress for new legislative
authorities. Scientists in the U.S. EPA Office
of Pesticide Programs were already laying
the groundwork for improvements in the
U.S. EPA risk assessment processes, includ-
ing incorporation ofchildren's dietary intake
levels into risk assessments and improve-
ments in the assessment processes for
developmental toxicity.
The 1996 law gives the agency one
uniform standard to use in registering all pes-
ticides and setting tolerances, which are the
limits of allowable pesticide residues on a
food. Previously there were three separate
standards for pesticides on food: risk/benefit
balancing for fresh fruits and vegetables, the
zero risk or Delaney clause standard for car-
cinogens on processed foods, and a public
health standard for processed foods generally.
The latter standard ofa "reasonable certainty
of no harm" was adopted as a single stan-
dard; this means negligible risk for a carcino-
gen. In making pesticide registration
decisions and in setting tolerances, the
agency now must consider available informa-
tion on aggregate exposure from all nonoccu-
pational exposures, induding drinking water
and exposures from lawn and household
uses. Previously, the U.S. EPAgenerally took
into account only the pesticide exposure
from food. The law also requires the U.S.
EPA to consider available information on
cumulative effects ofpesticide residues and
other substances that have a common mecha-
nism oftoxicity. Previously, the U.S. EPA
regulated each pesticide individually.
On top of these new considerations,
Congress directed the U.S. EPA to use an
additional 10-fold (10x) factor during the
decision-making process to account for pre-
and postnatal toxicity. This factor is to be
applied in addition to the inter- and
intraspecies factors and was recommended by
the NRC (2). In fact, the committee believed
that the U.S. EPA already applied that addi-
tional factor when it found significant pre-
natal developmental toxicity and urged the
agency to also applythe factorwhen postnatal
effects are found (2). The agency can elimi-
nate or reduce this additional 10x FQPA fac-
tor for children only ifit makes a finding that
reliable and complete data indicate a different
factor will be safe for infants and children.
Specifically, the FQPA instructed the U.S.
EPA:
In the case of threshold effects . an
additional tenfold margin ofsafety for the
pesticide chemical residue and other
sources ofexposure shall be applied for
infants and children to take into account
potential pre- and postnatal toxicity and
completeness ofthe data with respect to
exposure and toxicity to infants and chil-
dren. Notwithstanding such requirement
for an additional margin ofsafety, the
Administrator may use a different margin
ofsafety for the pesticide chemical residue
only if, on the basis ofreliable data, such
a margin will be safe for infants and
children. (4)
This provision has been especially contro-
versial, first, because industry opposed its
enactment in the first place, second, because
of disagreements among scientists about
whether it should have been required, and
third, because ofdifficulties in implementa-
tion, as discussed below.
Risk is a function ofhazard and exposure.
The basis ofmost pesticide health decisions is
hazard information from animal tests. The
most fundamental assumption in hazard
identification is that if a chemical is haz-
ardous to animals, it is assumed hazardous to
humans. A related assumption is that animal
testing predicts relative potency for humans.
When the U.S. EPAdeveloped the concept of
the reference dose (RfD), it recognized that
both interspecies differences and intraspecies
variability need to be taken into account
when usinganimal studies in assessing risks to
humans (5). For decades, the FDA had used
this approach (called an Acceptable Daily
Intake or ADI by FDA) in the regulation of
food additives under the Federal Food, Drug,
and CosmeticAct (6).
Generally, for noncancer effects, risk is
characterized as a percent ofthe RfD. The
chronic RfD is an estimate ofadailyexposure
to a population, which, over a 70-year life
span, is likely to have no significant deleteri-
ous effects (5). The acute RfD is its equiva-
lent for short-term exposure. To calculate an
RfD, the risk assessor first chooses the most
appropriate-usually the most sensitive-
effect from a chronic or acute study. Next,
the no-observable adverse effect level
(NOAEL) is identified for this effect. Finally,
the assessor identifies uncertainties in the data
and applies uncertainty factors to the
NOAEL-generally a 10x factor to account
for uncertainty in extrapolating from animals
to humans and a 1Ox factor to account for
the variation within the human population.
At the U.S. EPA, modifying factors between
3- and 10-fold are applied when critical
studies are missing.
Although application of these factors is
fundamental to risk assessment as we know it
today, few are aware oftheir origins. These
factors were not directly derived solely from
scientific experiments. Rather the FDA based
them on evaluation of a modest database,
along with a large portion ofscientific judg-
ment that supported the view that initially
one factor of 100 would cover all sources of
variability. Over time, this 100-fold factor
was split into two factors of10 (6).
Applying the additional FQPA 10x
factor to protect children has become one of
law's most challenging policy issues. While
the U.S. EPA applied modifying factors
when prenatal developmental studies were
incomplete, there was not a routine applica-
tion ofan additional 1Ox factor when signifi-
cant prenatal effects were observed. Further,
Congress directed the U.S. EPA to account
for uncertainties in exposure as well as haz-
ard. This was a new procedure with no
precedent for the U.S. EPA to use for its
application. Since enactment ofthe FQPA,
the U.S. EPA has issued successive draft poli-
cies describing criteria for removal of this
uncertainty factor.
An important policy question that has
emerged from the debate about the FQPA
10x factor is whether current toxicity testing
requirements and exposure information are
adequate to assure the safety of infants and
children, or whether the U.S. EPA should
routinely require additional information.
One question that has emerged that needed
to be answered quickly is whether the devel-
opmental neurotoxicity test (7), previously
conducted only iftriggered by results ofear-
lier testing, should be required by the U.S.
EPA for every food-use pesticide to fully
assess the potential for hazard to children.
The U.S. EPA has proposed that develop-
mental toxicity be assessed for all pesticides
that are neurotoxic, such as the organophos-
phate and carbamate pesticides (8).
Completely lacking in the testing battery
used by the U.S. EPA is a test to evaluate the
potential for developmental immunotoxic-
ity. Is the absence ofthis end point in cur-
rent testing relevant to the debate on
application ofthe FQPA lOx factor? A U.S.
EPA advisory committee on endocrine dis-
ruptor screening and testing recently recom-
mended development and validation of
several additional tests and end points to
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examine the potential for estrogen, androgen
and thyroid effects, and antagonism (9).
While these newefforts will add significantly
to knowledge about risks to children, how,
in the interim, should the U.S. EPA proceed
to make decisions?
This is a very complex issue with poten-
tially very large stakes. Consider the case of
the organophosphate pesticides (OPs). OPs
comprise some 40 insecticides on the market
in the United States that have been deter-
mined to act via a common mechanism of
toxicity, that is, via the mode of cholin-
esterase inhibition. Theoretically, prior to
FQPA, each pesticide could have been given
separate approvals to be present in the food
supply, in drinking water, and in residential
environments for a total exposure of 120
times the RfD for cholinesterase inhibition.
This means that the U.S. EPA could have
allowed total exposure to a level for cholin-
esterase inhibition less than one-tenth ofthe
NOAEL for animals. This is well within an
unacceptable range even without taking into
consideration the statute's FQPA lOx
Factor. Assuming that the U.S. EPA may
ultimately apply the 10x factor for none or
all ofthe OPs, the total allowable amount of
cholinesterase inhibition that could ever be
allowed by the U.S. EPA for organophos-
phates alone has been reduced by 120- to
1,200-fold. After including another class of
insecticides, the cholinesterase-inhibiting
carbamates, this allowable amount is likely
to be reduced even further. In reality, the
allowable amounts ofrisk were not used up
for each pesticide prior to the enactment of
the FQPA. Further, generous "default"
assumptions are being replaced with real-
world data that are lowering assessments of
risk for many OPs on the market. However,
some individual OPs, such as azinphos
methyl (guthion), have been found at levels
above the allowable levels even without
accounting for cumulative exposures from
other products (10). Therefore, it is clear
that there will be major changes for pesticide
use and marketing in the United States.
The FQPA has created challenges that call
forfurther research in this area. Afundamental
question that needs to be examined that
applies verybroadly is, What is the variation-
genetic, gender, age-related, and nutritional-
within the human population's response to
exogenous agents? We do not really know.
Government needs to work with the research
community not only to develop more expo-
sure and biological data and better models for
infants and for children but also to under-
stand genetic, aging, gender- related, and
other sources ofvariability. This in turn will
help strengthen the scientific underpinning
for a rational and systematic alternative to
uncertainty andsafety factors.
ToxicChemicals
There are approximately 85,000 chemicals
that have been produced in the United
States. Each year an additional 2,000-3,000
new chemicals are brought to the U.S. EPA
for review prior to manufacture. The U.S.
EPA estimates that about 15,000 of these
compounds are produced in quantities ofat
least 10,000 pounds or greater per year.
There has been no systematic gathering of
either hazard or exposure information for
these chemicals. The U.S. EPA has initiated
a major chemical-testing program-the first
chemical testing Congress has authorized in
20 years-for industrial chemicals and pesti-
cides. ByAugust 1999, the U.S. EPA was to
begin implementing a program to screen and
test pesticides and other chemicals for their
potential to disrupt endocrine systems of
wildlife and humans. Some chemicals, such
as dioxins, PCBs, and certain pesticides, have
been linked to sexual and reproductive devel-
opmental problems in both wildlife and lab-
oratory animals, and there is a strong
evidence for human effects as well. The U.S.
EPA convened a scientific panel, the
Endocrine Disruptor Screening and Testing
Advisory Committee, that has proposed pro-
tocols for the screening and testing ofmore
than 15,000 chemicals (9). Required by both
the FQPA and the Safe Drinking Water Act
of 1996, this is a huge undertaking. It
involves validating a number ofexisting in
vitro and in vivo tests and creating new tests
to detect the abilities ofchemicals to interact
with the estrogens, androgens, and thyroid
hormone systems.
In 1998, there were 2,863 high-
production-volume (HPV) chemicals that the
United States imported or produced at more
than 1 million pounds per year. In 1997 and
1998 Environmental Defense, the U.S. EPA,
and the Chemical Manufacturer's Association
concluded that insufficient information was
available to determine whether basic screening-
level data were available for HPV chemicals.
The U.S. EPA found that 43% have no test-
ingdata on basic toxicity, and only 7% have a
full set ofbasic test data. According to the
information that the U.S. EPA collected, for
78.2%, or 2,240 HPVs, there was no screen-
ing information for developmental toxicity.
For 716 HPVs that are present in consumer
products, nearly half (45.8%) were lacking
screening developmental toxicity informa-
tion. One-fourth (23.8%) ofthe 239 HPVs
for which the Occupational Health and
SafetyAdministration hadestablished permis-
sible exposure levels and one-fourth (23.6%)
ofthe 251 HPVs listed in the Toxics Release
Inventory lacked information about develop-
mental toxicity. Therefore, we often lack
basic screening-level information for develop-
mental toxicity even for chemicals commonly
present in commerce and in the workplace.
For non-HPVs, information is even more
scarce (11).
This lack of toxicity data compromises
the public's right to know about chemicals in
their homes, their workplaces, and the prod-
ucts they buy. In April 1998, Vice President
Gore issued a challenge to industry to come
forward with complete basic test data for
these HPV chemicals. In September 1998,
the Chemical Manufacturers Association,
Environmental Defense, and the U.S. EPA
announced a voluntary initiative to fill these
information gaps. (12).
The vice president also directed the U.S.
EPA to establish testing requirements for
chemicals to which children may be exposed.
This effort will examine several dozen chemi-
cals to which children are likely to be exposed
and ensure that they receive testing for poten-
tial hazards to children. The required testing
will be extensive-comparable to that
required for pesticides. At the time of the
writing of this article, it was uncertain
whether this program would be implemented
via rule making by the U.S. EPA or as a
voluntaryeffort bythechemical industry.
FederalInitiative
Executive order. In 1997, President Clinton
signed an historic executive order requiring
for the first time that all federal agencies
ensure that their policies and rules address
disproportionate environmental health and
safety risks to infants and children (13). The
U.S. Department of Health and Human
Services and the U.S. EPA recently moved to
establish the first federal research centers
dedicated solely to studying children's envi-
ronmental health hazards. Grants ofbetween
$1.2 and 1.6 million were awarded to estab-
lish eight federal research centers. Five ofthe
centers are studying the links between the
rise in asthma rates in children and environ-
mental factors, such as second-hand smoke,
smog, and other pollutants. The other three
centers are conducting research on children's
special vulnerability to pesticides (14). At the
U.S. EPA, there is an Office of Children's
Health Protection that is working in a num-
ber of areas to strengthen the U.S. EPA's
approach to protecting children. Through
the executive order, there are efforts under-
way across the government to better coordi-
nate activities to prevent asthma, birth
defects, childhood lead poisoning, childhood
cancer, and childhood injuries.
National expendituresfor research on
children. Many ofthe most important envi-
ronmental hazards to humans involve risks
to neurological development in children.
Lead, methyl mercury, and PCBs are exam-
ples of neurotoxic chemicals to which chil-
dren can be very sensitive. Overall, the
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research investment for children has been
modest. In 1995, the United States spent
$405 billion on education, two-thirds of
which were devoted to K-16 education.
Another $150 billion were spent on criminal
justice, health, and social welfare programs
for children for a total of $555 billion. Yet
the total amount ofmoney spent on research
related to children in 1995, in all categories
of effort, was only $2 billion (15). Thus,
there is in the United States a mismatch
between expenditures and research on inter~
ventions to enhance the well-being and
development ofchildren.
Public Health Considerations
Consider the magnitude ofthe public health
burden ofmajor developmental disabilities.
Developmental disabilities are a group of
physical, cognitive, psychological, sensory,
and speech impairments arising duringdevel-
opment and up to 18 years ofage. According
to the U.S. Centers for Disease Control and
Prevention (CDC), some 17% of all U.S.
children less than 18 years ofage have one or
more developmental disabilities. In the great
majority of cases, the cause is unknown.
Serious developmental disabilities, such as
autism, cerebral palsy, and mental retarda-
tion, account for much ofthe total cost to
society.
Autism
Autism, once believed to be a rare disorder, is
a complex developmental disorder with onset
and diagnosis during the first three years of
life. Autism is part ofa collection ofdisorders
referred to as pervasive development disorder
or autism spectrum disorder. These disorders
involve deficits in social interaction, commu-
nication, behavior, and imagination (16).
Some people with autism may function below
normal intellectual levels, while others may do
well in school but have severe social impair-
ments. Some never speak. Success in some
cases seems to be best with early education
and intervention. Autism may be associated
with specific structural brain abnormalities.
An estimated 135,000 United States children
ages 3-21 have been diagnosed with autism
and autism spectrum disorders. The preva-
lence is estimated at 1-2 per 1,000 children
under age 15 (17-20). The rate ofautism is
believed to be increasing both nationwide and
worldwide. Older research estimated the
prevalence ofautism to be only 0.4-0.5 per
1,000 children. Data from Europe are more
extensive, but in the United States, the only
effort to monitor prevalence ofand trends in
autism is the CDC system in metropolitan
Atlanta, Georgia. Although research indicates
that autism may involve interactions between
genetic susceptibility and environmental
exposures, there have been few efforts to link
autism cases with environmental exposure
levels.
Because we have so little information
about autism, it is difficult to assess the costs
to society. However, the CDC estimated
that, in 1995 alone, the total costs for special
education for autistic children in the United
States were more than $160 million (16). In
addition, 1 childwith autism can require resi-
dential care costing between $70,000 and
$100,000 per year (21). Families bear a
tremendous burden ofthe costs; they must
adjust in numerous ways, sometimes at the
cost ofa parent's career, to care for the autis-
tic child. In addition to these costs there is an
unknown but certainly significant burden
and cost to society for those children who are
not given adequate education when they are
young, and those with forms ofautism that
have long-term impacts on their functioning
in society.
In California, the number of children
with autism enrolled in statewide
Department ofDevelopmental Services pro-
grams rose from 3,864 in 1987 to 11,995 in
1998, an increase ofmore than 210% during
those 11 years. Bycomparison, enrollment of
children with other disorders such as cerebral
palsy and epilepsy increased by only 30-45%
for the same period (22). The rising number
of children diagnosed with autism may
reflect an actual increase or be due in part to
changes in diagnosis and reporting, specifi-
cally greater recognition of a broader and
subtler set ofsymptoms associated with the
disorder. For instance, autism spectrum dis-
orders include not only autism but also
Asperger's syndrome, childhood disintegra-
tive disorder, Rett's syndrome, and pervasive
developmental disorders. The changes in cri-
teria for diagnosis of autism complicate
efforts to understand trends ofprevalence
over time.
The cause or causes ofautism are not yet
known. A strong hereditary component was
discovered through earlystudies oftwins (23).
There is evidence for interactionwith environ-
mental factors such as pre- or postnatal expo-
sure to infectious diseases and exposure to the
drugs valproic acid and thalidomide (24).
Autism is known to be associated with birth
defects. Thalidomide when taken by a preg-
nantwoman between days 20 and 24 ofgesta-
tion not only causes a high rate ofmissing or
shortened limbs (phocomelia) but also has
been associated with a high rate ofautism
(25). This is the time of the closure ofthe
neural tube in fetal development, suggesting
that there could be an embryological origin to
autism. Further, a large percentage ofchildren
with autism have minor malformations ofthe
ear, which would occur in the same time
period, compared with children with and
without other developmental disorders (26).
Autopsy studies of humans and animal
models suggest that there is a very specific set
ofbrain anomalies associated with autism
(absence ofthe facial nucleus and superior
olive along with shortening ofone region of
the brain stem). These studies indicate that
these changes can be caused by either a
genetic abnormality (lack ofthe HoxA 1 gene
in mice) or exposure to an agent such as
thalidomide or valproic acid just after neural
tube closure during fetal development (27). A
recent link between autism and the
measles/mumps/rubella vaccine drew a great
deal ofattention but has not been validated
by research. A study in Great Britain found
no association between the vaccine and
autism (28).
Cerebral Palsy
Cerebral palsy (CP) is the most common
chronic motor (muscle) disorder in child-
hood. It is a group ofnonprogressive, but
often changing, motor impairment syn-
dromes secondary to lesions or anomalies of
the brain arising at any time during brain
development (29). People with CP have
abnormal control ofbody movement and of
posture. About 20% ofchildren with CP also
have major birth defects. About halfofchil-
drenwith CP also have global mental retarda-
tion (30). The risk of cerebral palsy is
strongly associated with birthweight and
preterm birth-the smaller the infant and the
younger the gestational age, the greater the
risk. Approximately one in every 20 very low
birth weight babies who survive infancy will
develop disabling CP, compared to 1 in
1,000 ofall normal birthweight infants.
CP is one ofthe most costlydevelopmental
disorders affecting children, adding an esti-
mated $500,000 in lifetime medical costs for
each affected child (31). One in every 500
children in the United States lives with some
form ofCP today (32-36). The prevalence of
cerebral palsy is believed to be remaining con-
stant or increasing slightly, possibly because
more very lowbirth weight infants are surviv-
ing as treatment improves; many of these
infants will suffer subsequent developmental
disabilities. Although very low birth weight
infants (< 1,500 g) are 100 times more likely
to develop disabling CP than infants ofthe
most common weight groups (37), the higher
number ofnormal birth weight babies results
in their contributing to more than halfofall
CP cases (38). Besides low birth weight and
preterm birth, other risk factors include being
born feet first, maternal bleeding, and certain
other adverse clinical signs in the newborn
period (39).
Mentl Retardtion
Mental retardation (MR) is a varied group
of conditions characterized by cognitive
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limitations due to organic brain dysfunction,
with onset no later than 18-22 years ofage
(40). The definition ofMR also is based on
functional limitations in areas that include
daily living skills, social skills, and commu-
nication. About 50% of children with MR
also have structural birth defects. In the
1995-1996 school year, approximately
600,000 U.S. school children age 6-21 with
MR were served in special education pro-
grams as required by law. Costs were $3.3
billion to the federal government and much
more for state and local governments (41).
The average cost ofcaring for children with
more serious MR is difficult to estimate, but
it may be as high as 10 times the cost ofpro-
viding for a child without a disability.
The cause of most cases ofMR among
children is unknown. Some environmental
factors include fetal alcohol syndrome, heavy
metals poisoning such as lead and methyl
mercury, and infections such as meningitis.
Environmental exposure to lead can cause a
general reduction in IQand, at high enough
doses, mental retardation. MR also occurs in
association with a number of major birth
defects, CP, very preterm birth, and very low
birth weight. Therefore, as with CP, identify-
ing causes ofMR is critical. Since 1991, the
CDC has tracked MR in metropolitan
Atlanta. According to the CDC, the preva-
lence of MR in 3- to 10-year-old children
between 1991 and 1994 was 9.7 per 1,000
children, orabout 1%.
We know very little about fundamental
issues related to the health and neurological
development ofchildren, including preva-
lence and trends for some ofthe most serious
developmental disabilities, autism, CP, and
MR. We know even less about which envi-
ronmental factors may be detrimental. We
have little information about developmental
toxicity and exposure ofchildren to pesticides
and even less information about industrial
chemicals. The result is that we do not know
how to prevent most childhood developmental
and behavioral disorders.
Conclusions
What kind ofresearch will be appropriate? A
research agenda for children's neurodevelop-
ment needs to be backed up by a strong
national public health information and assess-
ment function to understand the rates and
patterns ofdevelopmental disabilities in our
children. We do not have much information
on exposures to children, yet opportunities
exist. New findings in genetics and in
mechanism-based toxicology research provide
further opportunities to advance the field. A
stronger linkage between public health sur-
veillance and basic research efforts could help
identify relationships between environmental
exposures, as well as genetic components and
gene-environment interactions, and major
developmental disabilities.
Much of the recent early development
research has focused on socioeconomic status
as a measure ofearly childhood deprivation.
Lower socioeconomic status communities
and minority communities have dispropor-
tionate shares ofmany environmental expo-
sures as well as nutritional and other
disparities (42l. Collaboration between devel-
opmental and environmental researchers is
needed to elucidate the role ofenvironment
as a component ofearly childhood depriva-
tion. We need research that not only
addresses the most severe impacts but also
examines the relationship between population
exposures to neurotoxicants and the full con-
tinuum of intellectual, performance, and
behavioral measures. The cases oflead, PCBs,
and methyl mercury hold lessons that small
individual impacts, over an entire population,
can exact enormous costs to society.
An environmental prospective study may
be the best avenue to fully address several of
these concerns. Prospective studies were nec-
essary for the identification ofthe subtle long-
term neurodevelopmental impacts oflead and
PCBs to be identified. Prospective data col-
lection, beginning prenatally, could include a
broad range of environmental exposures.
Tools are available for assessing many impor-
tant risk factors, including genetic susceptibil-
ity, biomarkers ofenvironmental exposures,
and hormonal status. Long-range follow-up
ofchildren would be used to assess neuro-
development outcomes over time.
With the large number ofpoorly assessed
chemicals used in commerce known to be or
possibly harmful to development, such
research will be vital to ensure adequate pro-
tection for children. Ifthe 1990s was the
decade ofthe brain, perhaps the next decade
can be dedicated to using our newfound
knowledge on how the brain develops and
functions to identify and prevent causes of
developmental disabilities.
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